These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 4587529)

  • 1. Possible properties of microbodies (peroxisomes). Microbody proliferation and hypolipidemic drugs.
    Reddy JK
    J Histochem Cytochem; 1973 Nov; 21(11):967-71. PubMed ID: 4587529
    [No Abstract]   [Full Text] [Related]  

  • 2. Microbody proliferation in liver induced by nafenopin, a new hypolipidemic drug: comparison with CPIB.
    Reddy J; Svoboda D; Azarnoff D
    Biochem Biophys Res Commun; 1973 May; 52(2):537-43. PubMed ID: 4711169
    [No Abstract]   [Full Text] [Related]  

  • 3. Increase in hepatic carnitine acetyltransferase activity associated with peroxisomal (microbody) proliferation induced by the hypolipidemic drugs clofibrate, nafenopin, and methyl clofenapate.
    Moody DE; Reddy JK
    Res Commun Chem Pathol Pharmacol; 1974 Nov; 9(3):501-10. PubMed ID: 4445568
    [No Abstract]   [Full Text] [Related]  

  • 4. The peroxisome proliferation-associated polypeptide in rat liver.
    Reddy JK; Kumar NS
    Biochem Biophys Res Commun; 1977 Aug; 77(3):824-9. PubMed ID: 901515
    [No Abstract]   [Full Text] [Related]  

  • 5. [Peroxisomes and hypolipidemic agents ].
    Heller F; Pourbaix S
    Sem Hop; 1982 Jul; 58(28-29):1712-7. PubMed ID: 6289453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure, composition, physical properties, and turnover of proliferated peroxisomes. A study of the trophic effects of Su-13437 on rat liver.
    Leighton F; Coloma L; Koenig C
    J Cell Biol; 1975 Nov; 67(2PT.1):281-309. PubMed ID: 406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The proliferative response of hepatic peroxidomes of neonatal rats to treatment with SU-13 437 (nafenopin).
    Stäubli W; Schweizer W; Suter J; Weibel ER
    J Cell Biol; 1977 Sep; 74(3):665-89. PubMed ID: 903369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two hypolipidemic peroxisome proliferators increase the number of lamellar bodies in alveolar cells type II of the rat lung.
    Fringes B; Reith A
    Exp Mol Pathol; 1988 Apr; 48(2):262-71. PubMed ID: 3258252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nafenopin-induced proliferation of peroxisomes in the small intestine of mice.
    Psenicnik M; Pipan N
    Virchows Arch B Cell Pathol; 1977 Oct; 25(2):161-9. PubMed ID: 412313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nafenopin-induced hepatic microbody (peroxisome) proliferation and catalase synthesis in rats and mice. Absence of sex difference in response.
    Reddy JK; Azarnoff DL; Svoboda DJ; Prasad JD
    J Cell Biol; 1974 May; 61(2):344-58. PubMed ID: 4208071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further evidence to suggest that microbodies do not exist as individual entities.
    Reddy J; Svoboda D
    Am J Pathol; 1973 Mar; 70(3):421-38. PubMed ID: 4120301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hypolipidemic drugs, nafenopin and clofibrate, on the concentration of ligandin and Z protein in rat liver.
    Fleischner G; Meijer DK; Levine WG; Gatmaitan Z; Gluck R; Arias IM
    Biochem Biophys Res Commun; 1975 Dec; 67(4):1401-7. PubMed ID: 812503
    [No Abstract]   [Full Text] [Related]  

  • 13. [Peroxisomes and hypolipidemic agents (author's transl)].
    Heller F; Pourbaix S
    Pathol Biol (Paris); 1982 Apr; 30(4):220-5. PubMed ID: 7045781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properties of hypolipidemic peroxisome proliferators in the lymphocyte [3H]thymidine and Salmonella mutagenesis assays.
    Warren JR; Simmon VF; Reddy JK
    Cancer Res; 1980 Jan; 40(1):36-41. PubMed ID: 6765917
    [No Abstract]   [Full Text] [Related]  

  • 15. The effects of clofibrate ingestion on alveolar macrophage peroxisome content and oxygen metabolism.
    Drath DB; Davies P; Shorrey JM; Simpson P
    Agents Actions; 1982 Jul; 12(3):365-70. PubMed ID: 6291347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of DNA synthesis but not of peroxisomal beta-oxidation by nafenopin in primary cultures of marmoset hepatocytes.
    Bieri F; Stäubli W; Waechter F; Muakkassah-Kelly S; Bentley P
    Cell Biol Int Rep; 1988 Dec; 12(12):1077-87. PubMed ID: 3147145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of fatty acyl coenzyme A oxidase in the efflux of oxidized glutathione from perfused livers of rats treated with the peroxisome proliferator nafenopin.
    Conway JG; Neptun DA; Garvey LK; Popp JA
    Cancer Res; 1987 Sep; 47(18):4795-800. PubMed ID: 3621175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The hepatic effects of hypolipidemic drugs (clofibrate, nafenopin, tibric acid, and Wy-14,643) on hepatic peroxisomes and peroxisome-associated enzymes.
    Moody DE; Reddy JK
    Am J Pathol; 1978 Feb; 90(2):435-46. PubMed ID: 623209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A characteristic membrane protein of liver peroxisomes inducible by clofibrate.
    Hüttinger M; Goldenberg H; Kramar R
    Biochim Biophys Acta; 1979 Dec; 558(2):251-4. PubMed ID: 508747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitogenic effect in mouse liver induced by a hypolipidemic drug, nafenopin.
    Moody DE; Rao MS; Reddy JK
    Virchows Arch B Cell Pathol; 1977 Apr; 23(4):291-6. PubMed ID: 404752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.